• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Imidodisulfamide derivatives of formula (I) in which X is hydrogen, methyl, bromo or chloro; and Y is a benzeneaminosulfonyl radical of the formula in which R is hydrogen or methyl; R1 is hydrogen, bromo, chloro, nitro, methyl, trifluoromethyl or methoxy; and R2 is hydrogen, chloro or methyl provided that when R2 is chloro, R1 is chloro, methyl or trifluoromethyl and when R2 is methyl, R1 is methyl; and alkali metal salts of said compounds, which are useful in the treatment of allergic conditions, are prepared by reaction of an appropriately substituted tetrahydroisoquinoline and bis (chlorosulfonyl) imide in the presence of a tertiary amine.
    公开号:SU1017169A3
    申请号:SU813277099
    申请日:1981-04-13
    公开日:1983-05-07
    发明作者:Эльфехаил Али Фадиа
    申请人:Смит Клайн Корпорейшн (Фирма)；
    IPC主号:
    专利说明:

    fonil) -1,2,3,4-tetrahydroisoquinoline with m.p. 150-152 “C.
    Preparation of 7-, (3-chlorobenzolamino; phon) -1,2, 3,4-tetrahydroquinoline hydrochloride.
    A mixture of 43.3 g (OL18 mol) 2-acetyl-7- (3-chloro-6-ene-amino-aminosulfone) 1, 2,3,4-tetrahydroisoquinoline, 575..2USH 3N. hydrochloric acid and 60 ml of V) - butanol is heated under reflux for 3 hours. The mixture is concentrated under reduced pressure. The residue is treated with warm isopropanol, and 7- (3-chlorobenzene-aminosulfonyl) -1,2,2, 4-tetragon-shchrokhinolin-hydrochloride is isolated in the form of an off-white solid with m.p. 215217C.
    G Preparation of H, N-di17- (3-chlorobenzene-aminosulfone) -, 2,3,4-tetrahydroisoquinoline disulfonimide.
    To 8.05 g (0.038 mol) of dichlorosulfimnimide in 150 ml of anhydrous acetonitrile at -40 ° C, 11.4 g (O., 113 mol) of anhydrous triethylamine are added dropwise. Raise the temperature of the reaction mixture to and slowly add to it 27.0 g (0.075 mol) of 7- (3-chlorobenzene-aminosulfonyl) -1, 2,3,4-tetrahydroisoquinoline hydrochloride. in g (O, 098 mol of triethylamine and 200 ml of acetonitrile. The resulting mixture is stirred at 20 for about 16 hours. concentrated under reduced pressure at a temperature below 35 ° C. The residue is partitioned between ethyl acetate and dilute hydrochloric acid. The ethyl acetate fraction is separated, dried over anhydrous sulphate sodium filtered and the filtrate is concentrated under reduced pressure. The crude product is recrystallized from methanol to give N, N-di 17- (3-chlorobenzene-aminosulfonyl) -1,2,3,4 tetrahydroisoquinolyl disdulfonylimide with a melting point of 184-185,5 ° С .
    Found,%: 45.75; H 3.80; N 8.95; S 16.29
    Calculated,%: C 45.80; H 3.71; N 8.90, S 16.30
    Following the methods of Example 1, the appropriately substituted tetrahydroisoquinolines are reacted with a di - (hlbrosulfone) imide and the compounds listed in the table are isolated. The corresponding tetrahydroisoquinolines are obtained by reacting a suitable aniline derivative with 2-acetyl-7 chlorosulfone-1, 2,3,4-tetrahydroisoquinoline. with subsequent deacylation.
    Example 2. Obtaining 2-acetyl-7-chloro-6-chlorosulfonyl-1, 2,3,4 tetrahydroisoquinoline.
    A solution of 2.0 g (0.01 mol) of 2-acetyl-7-chloro-1, 2,3,4-tetrahydroisoquinoline in 15 ml of anhydrous chloroform is added dropwise to 20 ml of chlorosulfonic acid at. The reaction mixture is stirred at a temperature for 24 hours, then heated under reflux at 60 ° C for 2 hours. The reaction mixture is cooled, poured onto a trace (1 l) and extracted with methylene chloride. The organic phase is separated, dried with anhydrous magnesium sulfate, filtered, and the filtrate is concentrated under reduced pressure.
    Preparation of 2-acetyl-7H-chloro-6- (3-chlorobenzene-aminosulfonyl) -1,2,3.45 tetrahydroisoquinoline.
    A mixture of 1.5 g (1.6 mol) of 2-acetyl7-chloro -: - 6-chlorosulfonyl-1, 2,3,4 tetrahydroisoquinoline, 0.21 g (1.6 mol) of 3-chloroaniline, a few drops of pyridine and 5 ml of anhydrous acetone is heated under reflux for 16 hours. The reaction mixture is concentrated under reduced pressure, an oily residue is separated, which is then dissolved in
    5 methylene chloride. The organic solution is separated and washed with water, dilute hydrochloric acid, and water. The organic solution is then extracted with a 10% aqueous solution of sodium hydroxide and water. The mixed solution of sodium hydroxide hydrate and water is then washed with diethyl ether and acidified with 3 N;; CO. LAC acid. Crude product
    5 is dissolved in methylene chloride, dried over anhydrous magnesium sulphate and filtered. The filtrate is concentrated to dryness under reduced pressure.
    Preparation of N, N-di (7-chloro-6- (30 chlorobenzene aminosulfonyl) -1,2,3,4 tetrahydroisoquinolyl disulfonimide.
    2-Acetyl-7-chloro-L- (3-chlorobenzene aminosulfonyl) -1,2,3,4-tetrahydroisoquinoline is converted to M, N-di175 chloro-6- (3-chlorobenzene aminosulfone) 1, 2,3,4-tetrahydroisoquinolyl disulfonimide according to the methods described in example 1.
    Compounds of formula III which
    0 can be obtained using similar reactions as below.
    SoyaHa
    R
    R.
    R N otion,
    five
    n
    7-Br
    P
    17
    7-Br
    3-Br H
    18 19 20
    H N SI, 7-C1
    4-vNz h: n
    0
    4-C1 H7-C1
    4-CH5 3-C1 7-C1
    21
    n 3-Vg H7-h: 1 22
    n
    five
    Example 3. Preparation of 2-acetyl-7-chloro-8-chlorosulfonyl-1, 2,3, 4-tetrahydrois6quinoline,
    To a suspension of 16.0 g (0.32 mol) of sodium hydrate (50% oil on dispersion, washed with hexane) and 250 ml of anhydrous dimethylformamide in an atmosphere of argon gas are added dropwise 50 ml (0.43 mol) of benzylmercaptan in 100 ml of anhydrous dimethylformamide at. After the evolution of hydrogen ceased, 24.5 (0.1 mol) of 2-acetyl-7,8-dichloro1, 2,3,4-tetrahydroisoquinoline in 100 ml of anhydrous dimethylformamide was added to the reaction mass in 100 ml of anhydrous dimethylformamide at 20 cc. After b h, the reaction mixture is cooled, neutralized with concentrated hydrochloric acid. The dimethylformamide is removed under reduced pressure and the residue is treated with 300 ml of water. The aqueous residue is adjusted to pH 9 with 10% sodium hydroxide solution, the product is extracted with ethyl acetate (3 x 100 ml. The aqueous phase is acidified with concentrated hydrochloric acid; the crude product is obtained in white. The ethyl acetate is dissolved and dried over anhydrous sodium sulfate and a yellowish white solid is obtained with a mp of 95-111 C. This product is dissolved in 100 ml of glacial acetic acid and 30 ml of water. Chlorine gas is bubbled through the reaction mixture while stirring until 1-1 / 2 h Then to the reaction with If 100 ml of methylene chloride and 10 g of sodium bisulfite are added to 100 ml of water, the organic phase is separated and the aqueous phase is extracted with methylene chloride (2 x 50 ml). The organic phase and the combined extracts are dried over anhydrous sodium sulfate, filtered and the filtrate is concentrated to dryness by pressure, the desired product is isolated as a white solid with mp 121-125 C.
    Preparation of 2-acetyl-7-chloro-8 (3-chlorobenzene amino-sulphonyl) -1,2, 3,4-tetrahydrothioquinoline.
    A mixture of 11.0 g (0.36 mol) of 2-acetyl-7-chloro-3-chlorosulfonyl-1, 2,3,4 tetrahydroisoquinoline, 6.3 g (0.05 mol) of 3-chloroaniline, 8 ml of pyridine and 65 ml of acetone is converted to 2-acetyl-7-chloro9-8- (3-chlorobenzene-aminosulfonyl) -1,2,3,4-tetrahydroisoquinoline as a yellowish-white solid with mp. 193195 ° C, followed by a method that is similar to that used in Example 4
    P9 radiation N, N-di 7-chloro-8- (3 chlorobenzene aminosulfonyl) -1,2,3,4 tetrahydroisoquinolyl disulfonimide
    2-Acetyl-7-chloro-8- (3-chlorobenzene aminosulfonyl) -1,2,3,4-tetrahydroisoquinoline is converted to S, N-diE7 chloro-8- (3-chlorobenzene aminosulfonyl, 2,3,4-tetrahydroisoquinoline disulfonimide by the method described in Example 1. A white product is obtained with a melting point of 177.5-180 ° C.
    Found,%: C 42.01; H 3.08; N 8.30, S 15.02; C1 16.26
    Calculated,%: C 42.11; H 3.18; N 8.18, s 14.99; C1 16.57
    In addition, compounds of formula IV which are prepared using similar reactions, are as follows: Compound X
    R
    R,
    No
    H
    7-Br
    3-Vg
    7-C1
    CH,
    4-CH 3-CH N
    H 4-CH5 3-C1 7-C1
    H
    7-C1
    3-Vg
    H
    H
    PRI me R 4. Obtaining 2-acetyl-8-CHLORO-1, 2,3,4-tetrahydroisoquinoline.
    A mixture of 20.4 g (0.1 mol) of 8-chloro1, 2,3,4-tetrahydroisoquinoline hydrochloride, 9.85 g (0.12 mol) of sodium acetate, 40 ml of acetic anhydride and 100 ml of acetic acid is heated on a steam bath in for 3 h with stirring. After distilling off the solvent under reduced pressure, the residue is dissolved in water, the solution is alkalinized with a concentrated solution of ammonium hydroxide. The crude product is extracted with methylene chloride and the organic phase is washed with water, 10% hydrochloric acid, water and 5% aqueous sodium bicarbonate solution. The organic phase is then dried over anhydrous magnesium sulphate and then evaporated to dryness in vacuo to isolate 2-acetyl-8-chloro-1,2,3,4-tetrahydroisoquinoline as a yellow oil.
    Preparation of 2-acetyl-8-chloro-5 chlorosulfonyl-1, 2,3,4-tetrahydroisoquinoline.
    51.75 ml (0.78 mol) of chlorosulfonic acid is added dropwise with stirring to a solution of 20.7 g (0.099 mol) of 2-acetyl-8-chloro-1,2, 3,4-tetrahydroisoquinoline in 25 ml of methylene chloride at -70s. 10 ml of anhydrous chloroform is added to the reagent solution and the reaction mixture is stirred for 1 hour at -70 ° C. Then the reaction mixture is heated under reflux at 40-45 ° C for 2 hours and stirred at 20 ° C for 16 hours. Then the reaction mixture is poured into a pail of ice. The reaction product is extracted with methylene chloride (3x100 ml), the extract is washed with a saturated solution of sodium chloride, dried over anhydrous sodium sulfate and filtered. The filtrate is evaporated to dryness under reduced pressure, 2-acetyl-8-chloro-5-chlorosulfonyl-1,2,3 is isolated, tetrahydroisoquinoline is present as a whitish yellow solid with mp 10. Preparation of 2-acetyl-8-chloro-5- (3-chlorobenzene-aminosulfonyl) -, 2,3,4-tetrahydroisoquinoline. A mixture of 24.0 g (0.078 mol), 2-ee. -Til-8-chloro-5-chlorosulfonyl-1,2,3, tetrahydroisoquinoline, 12.7 g (0.1 mol) of 3-chloro-aniline, 15 ml of anhydrous pyridine and 110 m of anhydrous acetone is stirred at reflux for 3 hours. The reaction mixture is concentrated under reduced pressure, the residue is dissolved in methyl chloride, washed with dilute hydrochloric acid and then with water. A solution of methylene chloride is extracted with a 10% aqueous solution of sodium hydroxide and water. The mixed sodium hydroxide with water is washed with diethyl ether, then acidified with 3N. hydrochloric acid, the product is isolated and dissolved in ethyl acetate, dried over anhydrous sodium sulfate and activated charcoal, filtered, and the filtrate is concentrated under reduced pressure. The crude product is recrystallized from methanol, to give 2-acetyl-8-chloro-5- (3-chlorobenzene-aminosulfonyl) -1,2 3,4-tetrahydroisoquinoline as a white solid with mp. 185187С. Preparation of N, N-diE8-chloro-5- (3-chlorobenzene-aminosulfonyl) -1,2,3,4-tetrahydroisoquinolyl Disulfonimide .. . 2-Acetyl-8-chloro-5- (3-chlorobenzene aminosulfonyl) -1,2,3,4-tetrahyd roisoquinoline is converted to M, M-di 8 chloro-5- (3-chlorobenzenaminosulfonyl) -1,2,3,4 -tetrahydroisoquinolyl disulfonimide according to the methods described in Example 1. The product thus obtained is a yellowish-white solid with mp. 213-215 C. Found,%: C 42.46; t 3.20; N 8.27, s 15.16; C1 16.88% s C 42.11; H 3.18; N 8.18, s 14.99; C1 16.57 The following are the compounds of formula I, which are obtained using similar reactions: Compound R xj Y, I) H 8-Bg H 8-Bg 3-CH 8-CL H 8-C1 3-C1 8-C1 Frost. Preparation of the sodium salt of compound I. A solution of 350 mg of N, N-di (3-chlorobenzene aminosulfonyl) -1,2,3,4-tetrahydroisoquinolyl disulfonimide in 20 ml of methanol is passed through an ion exchange column (ER, 120-14.2 g of sulfonic acid resin in sodium form), the product elute with methanol, the eluate is evaporated almost to dryness, the resulting material is triturated with diethyl ether, filtered under nitrogen in the sediment - the target product with so pl. 155-160s. Found,%: C 44.66; H 3.49; N 8.66 Calculated,%: C 44.57; H 3.25; N, 8.72. The target salt can be obtained by treating 500 mg of Compound I with a solution of sodium methoxide (9 ml of 1.4 M) in methanol in an atmosphere of nitrogen at room temperature. Similarly, salts of the compounds of the invention with alkali metals are obtained. PRI me R 6. Obtaining 2-acetyl-5-chloro-7-chlorosulfonyl-1, 2,3,4 tetrahydroisoquinoline. A solution of 2-chloro-4-methoxyaniline in acetone is introduced into the reaction with methyl acrylate under the reaction conditions of Meerwein, 2-bromo (2-chloro-g4-methoxyphenyl) methyl propionate is obtained, the latter is debromed with zinc powder in acetic acid. The resulting 2-chloro-4methoxyphenylmethyl propionate is converted into 2-chloro-4-methoxyphenethyl isocyanate by reaction of the acid chloride derivative with sodium azide. The isocyanate is then cyclized to 5-chloro-7-methoxy-1, 2,3,4-tetrahydro-1-isoquinoline; the latter is then converted to tetrahydroisoquinoline using diborane in tetrahydrofuran. Tetrahydroisoquinoline is acylated with acetic anhydride before the methoxy group is converted to the hydroxy group with boron tribromide in methylene chloride. The resulting oxytetrahydroisoquinoline is converted into a mercapto derivative using a rearrangement of the dimethylthiocarbssmate derivative, followed by alkaline hydrolysis with sodium hydroxide in methanol. The mercaptotetrahydroisoquinoline bis-acylated was prepared with acetic acid anhydride and the thioacetate was selectively cleaved with sodium hydroxide. Then, mercaptotetrahydroisoquinoline is converted into the target chlorosulfonium compound with chlorine in ld acetic acid, followed by treatment with sodium bisulfite and sodium 2-acetyl-b-chloro-4-chlorosulfonyl, 2, 3, 4-tetrihydroisoquinoline, 2-acetyl-2-chlorosulfonyl, 2, 3, 4-tetrihydroisoquinoline, 2-acyl, 2 -bromo-5-chlorosulfonylg 1,2,2 tetrahydroisoquinoline and 2-acetyl-5methyl-b-chlorosulfonyl-1, 2,3,4-tet rahydroisoquinoline. The above-mentioned chlorosulfonyl tetra hydroisoquinolines are converted to the compounds according to the invention using the methods of Example 1 and appropriately substituted anilines. I Example. Preparation of 8-chloro-7-chlorosulfonyl-1,2,3,4-tetrahydroisoquinoline 2-acetyl. 7-methoxyisoquinoline is chlorinated by chlorine in acetic acid, the 8-chloro derivative is isolated and demethylated with 48% hydrobromic acid. The resulting 8-chloro-7-hydroisoquinoline is converted into 7 mercapto derivative with the help of an xanthate derivative, as described in Example 6. The obtained 8 chloro 77 mercapto isoquinoline is converted to the tetrahydro-derivative with the help of diborane dimethyl sulfide in methylene chloride. Mercaptotetrahydroivoquinoline is reacted with chlorine and the product obtained is treated with sodium bisulfite to isolate 2-acetyl 8-chloro-7-chlorosulfonyl-1,2,3,4 tetrahydroisoquinoline. 6-Chloro-8-methoxy-isoquinoline and 8-chloro-b-meth. Oxyisoquinoline are prepared from an appropriately substituted anisaldehyde using the Pomeranz-Fritsch method and converted into chlorosulfonyl compounds, as described above .. The resulting chlorosulfonyl compounds are converted into compounds proposed by the invention, using the methods of example 1 and using appropriately substituted anilines. Example 8. Preparation of 2-acetyl-5-chloro-8-chlorosulfonyl-1, 2, 3, -4-tetrahydrbisoquinoline, 5-aminoisoquinoline is contacted with hydrochloric acid, sodium nitrite and copper (I) chloride to form 5-chloroisoquinoline which is then reduced by diborane with tetrahydrofuran. Then, the resulting 5-chloro-tetrahydroisoquinoline is acetylated with acetic anhydride and chlorosulfonated with chlorosulfonic acid at a low temperature, for example at -50 ° C, to obtain the desired chlorosulfonyltetrahydroisoquinoline. The compounds of the invention are prepared using the methods of Example 1 and using appropriately substituted anilines. EXAMPLE 9 In order to obtain a composition according to the invention, the active ingredient, such as S, S-bis-7- (3-chlorobenzene aminosulfonyl) -1,2,3,4 tetrahydroisoquinolyl disulfonimide, is dissolved in sterile water at a concentration of 0.5 % and aerosol spray from the sprayer, which operates with a certain flow of air, adjusted to supply the desired weight of the drug. The proposed compounds are tested for biological activity. The antagonistic activity of the compounds of the invention against a slow-reacting anaphylaxis substance is measured by the ability of the active drug to suppress the contraction of guinea pig ileum caused by the slow-reacting anaphylaxis substance. In this test, parts of the ileum are cut out from guinea pigs and placed into 5 ml tissue vessels containing modified Tyrode solution . One end of the fabric is attached to a glass tissue holder, and the other end is attached to a displacement force transducer, and the fabric is placed under a load of 500 mg. Isometric cuts are recorded on a six-sided polygraph. The vessels are constantly aerated with a mixture of 95%. -5% CO. After 20 minutes of stabilization, a concentration of a suitable agonist is added to the tissue vessel, which provides a height of contraction amounting to 60-80% of the maximum achievable for a given agonist (determined from the entire reaction versus concentration curve obtained in separate experiments) , and record the reaction. The procedure is lost until reproducible results are obtained; For most agonists, two consecutive applications in combination with a third application, X5 min later, are sufficient for reproducibility. Experimental tissues are incubated with selected concentrations of the test compounds for 15 minutes. For experimental and control tissues, vessels were changed 5 times during incubation. During incubation, the vessels must be changed in order to guarantee the reproducibility of the response of the tissue to the agonist. The agonist at the same concentration is used in the presence of the test compound, the reaction is recorded and compared with the control. The percent inhibition provided by the test compound is calculated by subtracting the average percent change in control tissue from the average percent change in tissue exposed to the test compound. Additional compounds are then evaluated as long as the tissue retains a reproducible response to the agonist. Six tissues obtained from b animals are used simultaneously - 3 control and 3 experimental. The compounds of the invention, tested in concentrations from 1x10-M, show pronounced antagonism to the partially purified, slow-acting anaphylaxis substance obtained from a lightly piggy. The agonist is used at a concentration of 40 μg / ml. The illustrative results of this effect, given below, are the percent inhibition of the slow-reacting substance of anaphylaxis at various concentrations of the compound. Compounds of formula II Concentration, inhibition of H 3-C 1 n 3-C 5 63.0 Specificity of the antagonistic activity of the compounds according to the invention clearly demonstrate relatively low levels of inhibition in relation to such agonists as potassium chloride, serotonin, histamine and prostaglandins 2The pharmaceutical compositions of the invention contain a pharmaceutical carrier or diluent and some amount of a compound of formula I or an alkali metal salt thereof, which is sufficient to suppress asthma simpts and other allergies. diseases. When the pharmaceutical formulation is used in the form of a solution or suspension, examples of suitable pharmaceutical carriers or diluents include: for aqueous systems, water; for anhydrous systems, ethanol, glycerin, propylene glycol, corn oil, cottonseed oil, peanut oil, sesame oil, liquid paraffins, and mixtures thereof with water; for solid systems, lactase, kaolin and mannitol; and for aerosol systems, dichlorodifluoromethane, chlorotrifluoroethane and compressed carbon dioxide. In addition to the pharmaceutical carrier or diluent, compositions of the invention may include such ingredients as stabilizers, antioxidants, preservatives, lubricants, suspending agents, viscosity modifiers, etc. ., provided that the additional ingredients do not adversely affect the therapeutic effect of the positions according to the invention. The nature of the composition and the pharmaceutical carrier or diluent depends on the route of administration of the drug, i.e. parenterally or by inhalation. In particular, for the prophylactic treatment of asthma, the ' positions will have a form suitable for administration by inhalation. Thus, the compositions will contain a suspension or solution of the active ingredient in water, which can be administered with a conventional nebulizer. The compositions may contain a suspension or solution of the active ingredient in a conventional liquefied propellant or compressed gas in order to be injected from a pressurized aerosol container. The compositions may also contain a solid active ingredient, diluted with a solid diluent, for administration with the pores of a M11 inhalant. In the above compositions, the amount of carrier or diluent may vary, but preferably will comprise the bulk of the suspension or solution of the active ingredient. If the diluent is solid, it may be present in smaller, equal or larger quantities than the solid active ingredient.
    For parenteral administration, the pharmaceutical composition may have
    a form of sterile injectable liquid, such as ampoules, or a form of an aqueous or anhydrous liquid suspension.
    A conventional compound of formula (I) is administered in animals or in humans in compositions containing it in sufficient amounts to suppress the symptoms of an allergic reaction. When it is used in this way, the dosage of the composition is 0.5-500 mg of the active ingredient for each administration. For convenience, equal doses can be administered 1–4 times a day, with a daily dosage of 5 doses of approximately 0.5–2000 mg.
    Pharmaceutical preparations are prepared in conventional ways.
    CH $ 0
     + 1 I talk N O
    Table continuation
    权利要求:
    Claims (1)
    [1]
    The method of obtaining derivatives, bis- (tetrahydroi zohino n-Ν-, α ultrafon) -imides of the formula I
    1G $ 0 2 KN '
    - hydrogen, methyl, bromine, chlorine; -benzaminosulfonyl of the General formula II where X
    At
    R1 to 2 K 'where R is hydrogen, methyl;
    R is hydrogen, bromine, chlorine, nitro, 4 methyl, trifluoromethyl, methoxy;
    'K- is hydrogen, chlorine, methyl, provided that if R-g is chlorine, then R ^ is chlorine, methyl, trifluoromethyl, methoxy, and if r 2 is methyl, then R ^ is methyl, or their salts with an alkali metal , except for the fact that tetrahydroisoquinolines of the formula ΙΙΪ where the χ and Y values are indicated above are reacted with di (chlorosulfone) imide in the presence of triethylamine.
    Priority on the grounds: 04/14/80 in the compound of formula I X - hydrogen, bromine, chlorine;
    Y is benzaminosulfonyl-general formula II where R is hydrogen, methyl;
    R ^ is hydrogen, bromo, chloro, nitro, methyl, trifluoromethyl, methoxy;
    R a is hydrogen, chlorine, methyl, provided that R 2. is chlorine, then R ^ is chlorine, methyl, trifluoromethyl, if R ^ is methyl, then R 4 is methyl.
    06/13.80 in the compound of formula I X is hydrogen, methyl, bromo, chloro; y is benzaminosulfonyl of the general formula II where R is hydrogen, methyl;
    - hydrogen, bromine, chlorine, nitro, methyl, trifluoromethyl, methoxy; R 4 is hydrogen, chlorine, methyl, provided that R 2 is chlorine, then R; chlorine, methyl, trifluoromethyl, methoxy, if R ^ ~ methyl, then methyl.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1017169A3|1983-05-07|Process for preparing derivatives of bts-|-imides or their salts with alkali metal
    US3702849A|1972-11-14|4-| piperazine-1-carboxylic acid esters
    EP1879866B1|2011-03-16|Dihydropyridine derivatives
    EP0113782A1|1984-07-25|Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
    US4605653A|1986-08-12|1-|-1,6,7,11b-tetrahydro-2H,4H-[1,3]oxazino- or -thiazino-[4,3-a]isoquinoline derivatives and pharmaceutical compositions containing them
    SI9111318A|1997-10-31|Acetamide derivatives
    US4321254A|1982-03-23|Antiallergic imidodisulfamides
    AU600992B2|1990-08-30|Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids
    US4924004A|1990-05-08|1-phenyl-2-aminocarbonylindole compounds, preparation thereof and pharmaceutical compositions containing them
    US4317826A|1982-03-02|N,N'-Bis[substituted-1,2,3,4 tetrahydroisoquinolyl]disulfonylimides and antiallergic compositions and method of use
    US4350698A|1982-09-21|Antiallergic imidosulfamides
    US4350685A|1982-09-21|Antiallergic imidodisulfamides
    US4124587A|1978-11-07|4-Hydroxy-3-sulfinyl-quinolin-2|-ones
    PL144341B1|1988-05-31|Method of obtaining new heterocyclic compounds
    EP0072620A1|1983-02-23|3-Methylflavone-8-carboxylic acid esters
    EP0055899B1|1984-06-27|Antiallergic imidodisulfamides, process for their production and pharmaceutical compositions containing them
    US4292305A|1981-09-29|Antiallergic imidodisulfamides
    HU184848B|1984-10-29|Proces for producing imidodisulfemides and antyaliergistic pharmaceutical compositions containing them as active agents
    CA1159057A|1983-12-20|Process for preparing 7,8-dihydroxy-1-|-2,3,4,5-tetrahydro-1h-3-benzazepinederivatives
    LU82823A1|1981-02-02|NEW 1,2,4-OXADIAZINE DERIVATIVES, THEIR PRODUCTION, INTERMEDIATE PRODUCTS APPLICABLE TO THEIR PRODUCTION AND PHARMACEUTICAL AGENTS
    PL140094B1|1987-03-31|Process for preparing novel derivatives of 8-alkoxycarbonylamino-4-aryl-3-methyl-1,2,3,4-tetrahydroisoquinoline
    CS201042B2|1980-10-31|Method of producing etherified hydroxy-benzo-diheterocyclic compounds
    同族专利:
    公开号 | 公开日
    ES8207145A1|1982-09-01|
    GR75217B|1984-07-13|
    FI811082L|1981-10-15|
    DK149846B|1986-10-13|
    KR830005148A|1983-08-03|
    MX6697E|1985-10-21|
    PT72828A|1981-05-01|
    YU98081A|1983-10-31|
    AU536754B2|1984-05-24|
    ZW8381A1|1981-07-08|
    AU6920081A|1981-10-22|
    BG35328A3|1984-03-15|
    ES501195A0|1982-09-01|
    KR850000272B1|1985-03-15|
    RO81944A|1983-06-01|
    AR229160A1|1983-06-30|
    IE51220B1|1986-11-12|
    DK149846C|1987-06-29|
    NZ196773A|1983-07-15|
    EP0038177A1|1981-10-21|
    US4315935A|1982-02-16|
    IL62631A|1984-05-31|
    DE3160805D1|1983-10-06|
    EP0038177B1|1983-08-31|
    CA1162545A|1984-02-21|
    FI74702B|1987-11-30|
    PL230622A1|1981-12-23|
    CS222695B2|1983-07-29|
    DK160681A|1981-10-15|
    PL125404B1|1983-05-31|
    NO811278L|1981-10-15|
    PT72828B|1982-03-30|
    IE810829L|1981-10-14|
    RO81944B|1983-05-30|
    FI74702C|1988-03-10|
    DD158240A5|1983-01-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1384530A|1971-07-29|1975-02-19|Fisons Ltd|Chromone derivatives|
    AT352135B|1975-07-30|1979-09-10|Thomae Gmbh Dr K|Process for the preparation of new homophthalimides and their salts|
    AU506657B2|1975-12-10|1980-01-17|Wellcome Foundation Limited, The|Isoquinoline derivatives|
    US4192877A|1977-08-01|1980-03-11|Massachusetts General Hospital|Neuromuscular blocking agents|
    US4252818A|1979-08-02|1981-02-24|Merck & Co., Inc.|Novel benzopyran derivatives|GB1582884A|1977-05-19|1981-01-14|Beecham Group Ltd|Clavulanic acid derivatives their preparation and use|
    DK330880A|1979-08-03|1981-02-04|Beecham Group Ltd|PROCEDURE FOR THE PREPARATION OF CLAVULANIC ACID DERIVATIVES|
    EP0053893B1|1980-12-09|1985-03-20|Beecham Group Plc|Derivatives of clavulanic acid, their preparation and their use|
    US4562182A|1980-12-23|1985-12-31|Beecham Group P.L.C.|Compounds containing beta-lactams|
    US4385047A|1981-01-05|1983-05-24|Smithkline Beckman Corporation|Antiallergic imidodisulfamides|
    US4456757A|1981-03-20|1984-06-26|Asahi Kasei Kogyo Kabushiki Kaisha|Isoquinolinesulfonyl derivatives and process for the preparation thereof|
    US4350698A|1981-09-25|1982-09-21|Smithkline Corporation|Antiallergic imidosulfamides|
    US4678783B1|1983-11-04|1995-04-04|Asahi Chemical Ind|Substituted isoquinolinesulfonyl compounds|
    US4536510A|1983-07-22|1985-08-20|Smith Kline Beckman Corporation|Method of antagonizing the effects of thromboxane|
    GB8717374D0|1987-07-22|1987-08-26|Smith Kline French Lab|Pharmaceutically active compounds|
    DE19719817A1|1997-05-13|1998-11-19|Hoechst Ag|Substituted 6- and 7-aminotetrahydroisoquinoline carboxylic acids|
    US7229986B2|2000-05-16|2007-06-12|Takeda Pharmaceutical Company Ltd.|Melanin-concentrating hormone antagonist|
    WO2007022624A1|2005-08-22|2007-03-01|Transfert Plus, S.E.C.|Process for preparing sulfonylimides and derivatives thereof|
    JP5630048B2|2009-03-31|2014-11-26|セントラル硝子株式会社|Method for producing imido acid compound|
    JP5471045B2|2009-06-03|2014-04-16|セントラル硝子株式会社|Method for producing imidoate|
    AR080374A1|2010-03-05|2012-04-04|Sanofi Aventis|PROCEDURE FOR THE PREPARATION OF 2--N--1-METHYLPIRROLIDIN-2-IL) ETIL) - 1,2,3,4-TETRAHYDROISOQUINOLIN-7- SULFONAMIDE|
    TW201300358A|2011-03-14|2013-01-01|Taisho Pharma Co Ltd|Nitrogen-containing condensed heterocyclic compound|
    CN103524387A|2013-10-25|2014-01-22|中国海洋石油总公司|Preparation method of imidodisulfuryl fluoride lithium salt|
    CN109721037B|2019-03-11|2019-12-24|上海如鲲新材料有限公司|Novel process of bisimide salt|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US14002180A| true| 1980-04-14|1980-04-14|
    US06/159,340|US4315935A|1980-04-14|1980-06-13|N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use|
    [返回顶部]